

# The role of biomarkers in the diagnosis and prognosis of hepatocellular carcinoma.

Georgios Tsoulfas\*

Medical School, Aristotle University of Thessaloniki, Greece

## Introduction

Biomarkers play a critical role in the diagnosis and prognosis of hepatocellular carcinoma (HCC), the most common type of primary liver cancer [1]. HCC is often diagnosed at an advanced stage, making early detection essential for improving outcomes. The identification and validation of reliable biomarkers can facilitate early diagnosis, help assess disease progression, and guide treatment strategies [2].

One of the most widely studied biomarkers for HCC is alpha-fetoprotein (AFP). Elevated serum levels of AFP are commonly associated with HCC, and it is often used in clinical practice as a diagnostic tool [3]. However, while AFP can be useful in screening high-risk populations, such as individuals with chronic liver disease or cirrhosis, it is not specific to HCC and can be elevated in other conditions, including pregnancy and germ cell tumors. As such, AFP is typically used in conjunction with imaging techniques, such as ultrasound or magnetic resonance imaging (MRI), to confirm the diagnosis [4].

For instance, des-gamma-carboxy prothrombin (DCP) has shown promise as a marker for HCC. Elevated levels of DCP are associated with liver dysfunction and HCC development, and it may be particularly useful in patients with normal AFP levels [5]. Combining multiple biomarkers, including AFP, DCP, and imaging findings, can enhance the sensitivity and specificity of HCC diagnosis, allowing for more accurate assessments of disease presence [6].

Biomarkers such as TP53 mutations, chromosomal instability, and alterations in microRNA expression profiles have been linked to aggressive disease and poorer survival rates [7]. Understanding the molecular landscape of HCC through these biomarkers can help clinicians stratify patients based on their risk of disease progression and tailor treatment accordingly [8].

The advent of liquid biopsies is another exciting development in the field of biomarkers for HCC. Liquid biopsies allow for the non-invasive collection of blood samples to detect circulating tumor DNA (ctDNA), which can provide real-time insights into tumor dynamics [9]. The analysis of ctDNA can help identify genetic mutations and alterations associated with HCC, enabling earlier detection and monitoring of treatment response. This approach has the potential to revolutionize HCC management by allowing for more personalized treatment strategies and improved monitoring of disease progression [10].

## Conclusion

Biomarkers are essential in the diagnosis and prognosis of hepatocellular carcinoma. They facilitate early detection, improve diagnostic accuracy, and provide insights into disease progression and treatment responses. As research continues to uncover new biomarkers and refine existing ones, there is great potential for enhancing patient management in HCC. By integrating biomarker analysis into clinical practice, healthcare providers can develop more personalized approaches to HCC diagnosis and treatment, ultimately improving patient outcomes and survival rates in this challenging disease.

## References

1. Harding JJ, Khalil DN, Abou-Alfa GK. Biomarkers: what role do they play (if any) for diagnosis, prognosis and tumor response prediction for hepatocellular carcinoma?. *Dig Dis Sci.* 2019;64:918-27.
2. He S, Zhang DC, Wei C. MicroRNAs as biomarkers for hepatocellular carcinoma diagnosis and prognosis. *Clin Res Hepatol Gastroenterol.* 2015;39(4):426-34.
3. Lee NP, Cheung ST, Poon RT, et al. Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. *Biomark Med.* 2007;1(2):273-84.
4. Johnson P, Zhou Q, Dao DY, et al. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol.* 2022;19(10):670-81.
5. Mir IH, Jyothi KC, Thirunavukkarasu C. The prominence of potential biomarkers in the diagnosis and management of hepatocellular carcinoma: current scenario and future anticipation. *J Cell Biochem.* 2022;123(10):1607-23.
6. Parizadeh SM, Jafarzadeh-Esfehani R, Ghandehari M, et al. MicroRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. *Curr Drug Targets.* 2019;20(11):1129-40.
7. Xu RH, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. *Nat Mater.* 2017;16(11):1155-61.
8. Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of  $\alpha$ -fetoprotein in hepatocellular carcinoma: both or neither?. *Am J Gastroenterol.* 2006;101(3):524-32.

\*Correspondence to: Georgios Tsoulfas, Medical School, Aristotle University of Thessaloniki, Greece. E-mail: tsoulas@aut.gr.in

Received: 22-Aug-2024, Manuscript No. JGDD-24-148634; Editor assigned: 23-Aug-2024, Pre QC No. JGDD-24-148634(PQ); Reviewed: 06-Sep-2024, QC No. JGDD-24-148634;

Revised: 11-Sep-2024, Manuscript No. JGDD-24-148634(R); Published: 18-Sep-2024, DOI: 10.35841/jgdd-9.5.226

9. Zhang Y, Wang Y, Liu H, et al. Six genes as potential diagnosis and prognosis biomarkers for hepatocellular carcinoma through data mining. *J Cell Physiol.* 2019;234(6):9787-92.
10. Fartoux L, Decaens T. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. *Clin Res Hepatol Gastroenterol.* 2011;35:21-30.